QVAR (beclomethasone dipropionate HFA) Inhalation Aerosol
QVAR Patient Assistance Program

Thank you for your interest in the

TEVA Assistance Program

To qualify for assistance from this program, patients must:

  • Be a resident of the United States, Puerto Rico, or the Virgin Islands
  • Not be eligible for any prescription drug benefits through any private or public insurer/payer/program
  • Have a total family income of 200% or below the federal poverty level for your patient's state
  • Have a prescription for one or more of the Teva medicines listed on the application

To enroll:

  • Click here to download a copy of the application with instructions to complete and return to your healthcare professional.
    Patients will be notified by mail of program acceptance or denial
  • If patient is approved for assistance, you will receive a form to complete and return. The patient's medicine(s) will be shipped to your office directly from the Teva pharmacy
  • Once the patient is approved for the program, he or she will be eligible to receive assistance for up to 12 months. Renewals will be handled on a per-patient basis
If you have any questions, call the Teva Assistance Program toll-free number:

1-877-254-1039

Brought to You by the Marketers of
QVAR (beclomethasone dipropionate HFA) Inhalation Aerosol

References
  1. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest. 2002;122:510-516.
  2. Leach CL. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol. 1999;104:S250-S252.
QVAR® is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age or older. QVAR® is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR® may reduce or eliminate the need for systemic corticosteroids.

Important Safety Information


QVAR® does not replace fast-acting (rescue) inhalers for sudden symptoms.

CAUTION: If you are switching from an oral corticosteroid to QVAR®, follow your doctor's instructions to avoid health risks when you stop using oral corticosteroids (See WARNINGS, Prescribing Information).

Inhaled corticosteroids may cause a reduction in growth rate. The long-term effect on final adult growth is unknown.

In clinical studies, common side effects included headache and pharyngitis.

Do not stop taking QVAR® abruptly without talking to your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

110083